FAQ

NCO 700

Known as: NCO-700 
 
National Institutes of Health

Topic mentions per year

Topic mentions per year

1982-2000
01219822000

Related topics

Related topics

1 relation

Broader (1)

Piperazines

Related mentions per year

Related mentions per year

1948-2018
19401960198020002020
NCO 700
Piperazines

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
1998
1998
Inhibition of cathepsin B does not affect the intracellular activation of trypsinogen by cerulein hyperstimulation in isolated rat pancreatic acinar cells.
Activation of trypsinogen is thought to trigger the autodigestive process in acute pancreatitis. The lysosomal enzyme cathepsin B… (More)
Is this relevant?
1994
1994
A protease inhibitor, NCO-700, improves the contractile function in stunned canine myocardium.
To explore the role of calcium-dependent protease in the stunned myocardium, open-chest dogs underwent 15 min of left anterior… (More)
Is this relevant?
1991
1991
Effect of NCO-700, an inhibitor of protease, on lysosomal rupture in the ischemic myocardium.
The effect of NCO-700 (1), a protease inhibitor, on subcellular distribution of lysosomal enzymes was studied in the ischemic… (More)
Is this relevant?
1989
1989
Collagen-stimulated human platelet aggregation is mediated by endogenous calcium-activated neutral protease.
To clarify the physiological role of calcium-activated neutral protease (CANP) in human platelets, we loaded the platelets with a… (More)
  • figure 1
  • figure 2
  • figure 3
  • table 1
  • figure 4
Is this relevant?
1988
1988
Effect of NCO-700, an inhibitor of thiol protease, on reactive oxygen production by chemotactic peptide-stimulated rabbit peripheral granulocytes
The specific thiol protease inhibitor, NCO-700, which is related to L-trans-epoxysuccinylpeptides, inhibited oxidant production… (More)
  • table 1
  • table 2
  • table 3
Is this relevant?
1986
1986
Suppression of myocardial protein degradation by the protease inhibitor bis[ethyl(2R,3R)-3-[(S)-methyl-1-[4-(2,3,4-tri-methoxy-phenyl-methyl) piperazine-1-ylcarbonyl]butyl-carbonyl]oxiran-2…
The synthetic protease inhibitor bis[ethyl(2R,3R)-3-[(S)-methyl-1-[4-(2,3,4-tri-methoxyphenyl-methyl) piperazine-1-ylcarbonyl… (More)
Is this relevant?
1986
1986
Temporary salvage of ischemic myocardium by the protease inhibitor bis[ethyl(2R,3R)-3-[(S)-methyl-1-[4-(2,3,4-trimethoxyphenyl-methyl) piperazin-1-ylcarbonyl]butyl-carbonyl]oxiran-2-carbo xylate…
The administration (i.v., 20, 40 and 60 mg/kg) of the thiol protease inhibitor bis[ethyl(2R, 3R)-3-[(S)-methyl-1-[4-(2,3,4… (More)
Is this relevant?
1985
1985
Effect of NCO-700, an inhibitor of protease, on myocardial pH decreased by coronary occlusion in dogs.
During myocardial ischemia in dogs effects of NCO-700, a protease inhibitor on myocardial pH, were investigated. Ischemia was… (More)
Is this relevant?
1985
1985
Inhibition with NCO-700, a protease inhibitor, of degradation of cardiac myofibrillar proteins during ischemia in dogs.
NCO-700 is a newly synthesized inhibitor of both cathepsin B and calcium-activated neutral protease. We examined whether NCO-700… (More)
Is this relevant?
1982
1982
Reduction of experimentally produced acute myocardial infarction size by a new synthetic inhibitor, NCO-700, against calcium-activated neutral protease.
Calcium-activated neutral protease (CANP) might be involved in the irreversible degradation of myocardial proteins in the… (More)
Is this relevant?